Pain Medicine
SectionEditor: SpencerS.Liu
The Prevention of Chronic Postsurgical Pain Using
Gabapentin and Pregabalin: A Combined Systematic
Review and Meta-Analysis
Hance Clarke, MSc, MD, FRCPC,*†‡ Robert P. Bonin, PhD,§ Beverley A. Orser, MD, PhD, FRCPC,†‡
Marina Englesakis, BA MLIS,(cid:1) Duminda N. Wijeysundera, MD, PhD, FRCPC,*‡¶# and Joel Katz, PhD**
BACKGROUND:Many clinical trials have demonstrated the effectiveness of gabapentin and
pregabalinadministrationintheperioperativeperiodasanadjuncttoreduceacutepostoperative
pain.However,veryfewclinicaltrialshaveexaminedtheuseofgabapentinandpregabalinforthe
prevention of chronic postsurgical pain (CPSP). We (1) systematically reviewed the published
literature pertaining to the prevention of CPSP ((cid:1)2 months after surgery) after perioperative
administration of gabapentin and pregabalin and (2) performed a meta-analysis using studies
thatreportsufficientdata.Asearchofelectronicdatabases(Medline,Embase,CochraneCentral
Register of Controlled Trials, Cochrane Database of Systematic Reviews, IPA, and CINAHL) for
relevantEnglish-languagetrialstoJune2011wasconducted.
METHODS:Thefollowinginclusioncriteriaforidentifiedclinicaltrialswereusedforentryintothe
presentsystematicreview:randomization;double-blindassessmentsofpainandanalgesicuse;
report of pain using a reliable and valid measure; report of analgesic consumption; and an
absenceofdesignflaws,methodologicalproblemsorconfoundersthatrenderinterpretationof
the results ambiguous. Trials that did not fit the definition of preventive analgesia and did not
assesschronicpainat2ormoremonthsaftersurgerywereexcluded.
RESULTS:Thedatabasesearchyielded474citations.Elevenstudiesmettheinclusioncriteria.
Of the 11 trials, 8 studied gabapentin, 4 of which (i.e., 50%) found that perioperative
administrationofgabapentindecreasedtheincidenceofchronicpainmorethan2monthsafter
surgery.The3trialsthatusedpregabalindemonstratedasignificantreductionintheincidence
ofCPSP,and2ofthe3trialsalsofoundanimprovementinpostsurgicalpatientfunction.Eight
studieswereincludedinameta-analysis,6ofthegabapentintrialsdemonstratedamoderate-
to-large reduction in the development of CPSP (pooled odds ratio [OR] 0.52; 95% confidence
interval[CI],0.27to0.98;P(cid:1)0.04),andthe2pregabalintrialsfoundaverylargereductionin
thedevelopmentofCPSP(pooledOR0.09;95%CI,0.02to0.79;P(cid:1)0.007).
CONCLUSIONS:The present review supports the view that perioperative administration of
gabapentinandpregabalinareeffectiveinreducingtheincidenceofCPSP.Better-designedand
appropriately powered clinical trials are needed to confirm these early findings. (Anesth Analg
2012;115:428–42)
T
hedevelopmentofchronicpostsurgicalpain(CPSP) the limitations of the current literature and future direc-
is an unfortunate consequence of surgery that ad- tionsforclinicaltrials.Finally,weprovideanoverviewof
verselyimpactsthepatient’squalityoflife.Effortsto recentbasicsciencestudiesthatsuggestnovelmechanisms
prevent the establishment of CPSP include perioperative that may be responsible for some of the behavioral prop-
administration of a variety of drugs. We systematically ertiesofgabapentinandpregabalin.
reviewedthepublishedliteraturepertainingtothepreven- The factors that influence the transition from acute
tion of CPSP after perioperative interventions using gaba- postoperativepaintoCPSPhaveyettobeelucidated.CPSP
pentinandpregabalin.Afterdefiningpreventiveanalgesia has been defined as pathological pain that persists for
we present the results of the systematic review and meta-
longerthan2monthsaftersurgery.1Severalpatient-related
analysis,followedbyadiscussionoftheresults,including andsurgicalfactorshavebeenlinkedtothedevelopmentof
CPSP.2 The most consistent patient factor is the presence
and/orintensityofpreoperativeandpostoperativepain.3–5
Authoraffiliationsarelistedattheendofthearticle.
Because moderate to severe postoperative pain is a fre-
AcceptedforpublicationDecember15,2011.
quentoccurrenceaftersurgery,6noveldrugssuchasgaba-
Studyfundinginformationislistedattheendofthearticle.
pentinandpregabalininadditiontotraditionalopioidsare
Theauthorsdeclarenoconflictsofinterest.
administeredwiththeaimofprovidingsuperiorpainrelief
Reprintswillnotbeavailablefromtheauthors.
AddresscorrespondencetoHanceClarke,MSc,MD,FRCPC,Departmentof at rest and with movement, reducing opioid consumption
AnesthesiaandPainManagement,TorontoGeneralHospital,200Elizabeth andreducinganalgesic-relatedadverseeffects.7–9Ifdrugs,
Street,EatonNorth3EB317,PainResearchUnit,Toronto,ONM5G2C4,
suchasgabapentinandpregabalin,canpreventtheestab-
Canada.Addresse-mailtohance.clarke@utoronto.ca.
lishment of surgery-induced central sensitization and can
Copyright©2012InternationalAnesthesiaResearchSociety
DOI:10.1213/ANE.0b013e318249d36e decrease postoperative pain,10–12 then these drugs, given
428 www.anesthesia-analgesia.org August2012•Volume115•Number2
during the perioperative period, may also play a role in The following databases were searched: Medline, Embase,
preventingthetransitionofacutepaintochronicpain.13,14 Cochrane Central Register of Controlled Trials, Cochrane
Neuropathic pain, which is defined as pain initiated or Database of Systematic Reviews, International Pharmaceuti-
caused by a primary lesion or dysfunction in the nervous cal Abstracts (IPA, accessed via the OvidSP platform) and
system,15 has been implicated as a major contributor to the Cumulative Index to Nursing & Allied Health Literature
development of CPSP.2,16 Given that both gabapentin and (CINAHL,accessedviatheEbscoHostplatform).Thesearch
pregabalin are front-line treatments for patients suffering strategy contained 3 components: pregabalin or gabapentin
fromestablishedchronicneuropathicpain,17,18itisplausible terms, including generic and trade names, chemical abstract
thatthesedrugs,whenusedintheperioperativesetting,may service (CAS) registry numbers, MeSH or Emtree or text
be of benefit in reducing the incidence and/or intensity of words;preemptive,preventive,orperioperativeterms,using
chronicpain. MeSH or Emtree or text words; and finally, chronic pain
terms, using MeSH or Emtree or text words (Appendix 1).
PREVENTIVE ANALGESIA These 3 components were combined using the Boolean op-
Preventiveanalgesiahasevolvedfrompreemptiveanalgesia erator, “AND,” to obtain the intersection of the 3 sets; the
byshiftingthefocusfromblockingsolelynoxiouspreopera- resultswerelimitedtohumansubjectsandEnglish-language
tive stimuli12,19–21 to a broader conceptualization involving articles. All databases were searched in their entirety to the
blocking noxious stimuli across the entire perioperative pe- endofJune2011;however,theEmbasedatabasewaslimited
riod.13,14,22 A preventive analgesic effect is demonstrated tosearchesfrom2006to2011.
when postoperative pain and/or analgesic consumption is
reducedinrelationtoanintervention,aslongastheeffectis Inclusion Criteria
observedatatimethatexceedstheexpectedclinicalduration All clinical trials were evaluated according to the following
of action of the target drug. We have defined a preventive inclusion criteria for entry into the present review: random-
analgesiceffectasonethatisdemonstratedwhenpostopera- izedassignmentofpatientstotreatmentgroups;double-blind
tivepainand/oranalgesicusearereducedbeyond5.5half- assessmentsofpainandanalgesicuse;reportofpainusinga
livesofthetargetdrug.12,13,22Thisrequirementensuresthat reliableandvalidmeasure;reportofanalgesicconsumption;
theobservedeffectsarenotdirectanalgesiceffects.12,13 andanabsenceofdesignflaws,methodologicalproblems,or
confoundersthatrenderinterpretationoftheresultsambigu-
GABAPENTIN (NEURONTIN, PFIZER, INC.) AND ous.22 Trials that did not fit the definition of preventive
PREGABALIN (LYRICA, PFIZER, INC.) analgesia14 and did not assess chronic pain at 2 or more
Gabapentin, a structural analog of (cid:2)-aminobutyric acid monthsaftersurgerywereexcluded.
(GABA),wasinitiallyusedasananticonvulsantinthelate
1980s.Clinically,gabapentindemonstratedpoorefficacyas Data Extraction
an anticonvulsant.23 The antinociceptive properties of this Tworeviewers(H.C.andJ.K.)independentlyreviewedthe
drug, along with the advantage of producing only mild abstracts of each reference identified by the above search
side effects, made gabapentin an attractive therapeutic strategy,independentlyevaluatedeachincludedstudyfor
optionforpainspecialistswhousedotheranticonvulsants content, and completed a data extraction table that in-
with significant adverse events (i.e., carbamazepine) for cludedrelevantdata.Studieswereincludedifbothreview-
chronicpainconditions.23Bythelate1990s,gabapentinhad ersagreedthatthestudiesmettheinclusioncriteria.
become a first-line treatment for patients who suffered
fromchronicneuropathicpain.24,25Inrecentyears,gabap- Assessment of the Methodological Quality and
entinhasbeenusedwidelyasanadjunctforthetreatment Risk of Bias
of acute postsurgical pain. Several meta-analyses have Tworeviewers(H.C.andJ.K.)independentlyassessedthe
confirmed the efficacy of gabapentin in reducing postop- methodological quality of the included trials according to
erativeopioiduseandpain.26–28 theDelphicriterialist.38TheDelphilistidentifies9criteria
Pregabalinisstructurallysimilartogabapentinandwas forqualityassessment(Table1).
alsomarketedprimarilyforepilepsyandneuropathicpain.
Pregabalin (S-[(cid:2)]-3-isobutylgaba) was designed as a Statistical Analysis
lipophilic GABA analog substituted at the 3(cid:3) position to Meta-analysiswasusedtocalculatepooledeffectsofgabap-
facilitate diffusion across the blood–brain barrier.29,30 Pre- entinorpregabalinonthedevelopmentofchronicpainat3to
gabalin has also been found to be effective at reducing 6monthsaftersurgery.Forcasesinwhichastudyreported
acutepostoperativepain.10,31–36 theratesofchronicpaindevelopmentofchronicpainatboth
Studies have reported the effects of the gabapentinoids 3and6months,weincludedonly6-montheventratesinthe
inthepreventionofCPSP.Wesystematicallyreviewedthe statisticalanalysis.Summaryeffectswereexpressedaspooled
published, clinical trials pertaining to the prevention of odds ratios (OR) with associated 95% confidence intervals
CPSP ((cid:1)2 months after surgery) after perioperative inter- (CI).Initially,statisticalheterogeneitywasassessedusingthe
ventionsusinggabapentinandpregabalin. I2statistic,39,40whichdescribestheproportionoftotalvaria-
tionexplainedbybetween-studiesvariationinsteadofchance.
METHODS HigherI2statisticsimplymoreheterogeneitybetweenstudies
Search Strategy thanwouldbeexpectedbychancealone.Inthepresenceof
AsearchstrategywasdevelopedusingtheMedlinedatabase low heterogeneity (I2 (cid:3) 25%), pooled ORs were calculated
and subsequently translated into the remaining databases. underthefixed-effectsmodel;otherwise,therandom-effects
August2012•Volume115•Number2 www.anesthesia-analgesia.org 429
GabapentinandPregabalinPreventChronicPostsurgicalPain
Table 1.Methodological Quality Assessment
Intention-
Pointestimates to-treat
Treatment Similar Specified Outcome Care ofvariabilityfor analysisfor Total
allocation groupsat eligibility assessor provider Patient primaryoutcome postoperative quality
Study Randomization concealed? baseline? criteria? blinded? blinded? blinded? measures? outcomes? score/9
Amretal.(2010)46 Y Y Y Y Y Y Y N N 7
Buvanendranetal.(2010)31 Y Y Y Y Y Y Y Y Y 9
Broglyetal.(2008)50 Y Y Y Y Y ? Y N N 6
Burkeetal.(2010)34 Y Y Y Y Y Y Y Y N 8
Clarkeetal.(2009)49 Y Y Y Y Y Y Y Y N 8
Fassoulakietal.(2002)51 Y Y Y Y Y Y Y N N 7
Fassoulakietal.(2005)52 Y Y Y Y Y Y Y N N 7
Mooreetal.(2011)45 Y Y Y Y Y Y Y Y N 8
Pesonenetal.(2011)53 Y Y Y Y Y Y Y Y N 8
Senetal.(2009)48– Y Y Y Y Y ? Y Y N 7
hysterectomy
Senetal.(2009)47– Y Y Y Y Y Y Y Y N 8
hernia
Note:ThelistedcriterionaretakenfromtheDelphiconsensusforqualityassessmentofrandomizedclinicaltrials.
Ahigherscoreindicateshigherstudyquality.?(cid:1)Notreported;N(cid:1)No;NA(cid:1)notapplicable;Y(cid:1)Yes.
model was used. In addition, a subgroup analysis based on
the drug administered was performed, with a statistical
test-of-interaction being used to assess for subgroup differ-
ences.Finally,funnelplots41andthetestofHarbordetal.42
wereusedtotestforanypublicationbias.
Statisticalsignificancewasdefinedbya2-sidedPvalue
(cid:4)0.05,andallanalyseswereperformedusingStataVersion
11.2 (StataCorp Inc., College Station, TX). Our review
complies with the guidelines set forth by the Preferred
ReportingItemsforSystematicReviewsandMeta-Analysis
(PRISMA).43,44
RESULTS
Search Results
The database search yielded 474 citations, of which 64
studies were retrieved and examined; 11 studies met the
inclusioncriteria(Fig.1).31,34,45–53
Assessment of Methodological Quality
Table 1 summarizes the assessment of methodological
quality of the 11 clinical trials. All studies were double-
blind,randomized,controlledtrialswithspecifiedeligibil-
ity criteria listed. Outcome assessors were blinded in all
studies.Only1studyreportedanintention-to-treatanalysis
forpostoperativeoutcomes.31
Study Characteristics
Figure1.Selectionprocessforsystematicreview.
The 11 studies are summarized in Table 2. The studies
examinedthepreventiveeffectsofgabapentinorpregaba-
linonCPSP((cid:1)2monthsaftersurgery)andwerepublished The clinical heterogeneity is considerable among the 11
betweenOctober2002andJune2011.Atotalof930patients trialspresentedinthissystematicreviewandmeta-analysis.
were included in the trials. The sample sizes ranged from The studies using gabapentin varied with respect to the
n (cid:1) 30 to n (cid:1) 240, with a median of n (cid:1) 50. The surgical dosingregimenandtheperioperativeadministration.Fiveof
populationsstudiedwereasfollows:breastsurgery,46,51,52 the 8 gabapentin studies administered a single preoperative
totalkneearthroplasty,31totalhiparthroplasty,49cesarean dose of gabapentin,45,47–50 3 studies used a single preopera-
delivery,45 thyroidectomy,50 cardiac surgery,53 lumbar tive dose of 1200 mg,47,48,50 and the 2 other studies used a
discectomy,34inguinalherniorraphy,47andabdominalhys- single600-mgpreoperativedose.45,49Theremaining3studies
terectomy.48 Eight trials studied the effects of gabapen- startedgabapentinadministrationbeforesurgeryandcontin-
tin,45–52and3trialsstudiedtheeffectsofpregabalin31,34,53 uedeither1200mgofgabapentindailyfor8or10days,51,52or
on the prevention of pain that persisted for at least 2 300mgfor10dayspostoperatively.46Finally,thepregabalin
monthsaftersurgery. studies were also variable with respect to the timing and
430 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA
Table 2.Study Characteristics
Measurement
Study Designandsample Intervention Outcomemeasuresintravenous timepoints
Amretal. Date:NR Perioperativeintervention Primaryoutcome:Postopopioid T1(cid:1)dailypain
(2010)46 Design:3groupRCT RCT:Breastsurgery consumption scoresand
N(cid:1)150(Ven:n(cid:1)50;Gpn: F:(G1)oralVen37.5mg/day Secondaryoutcomes:Painscores opioid
n(cid:1)50;C:n(cid:1)50) startedthenightbeforesurgery perioperativelyanddailyuntil consumption
Samplecharacteristics:Low-risk andcontinuedfor10days 10dayspostop untilpostopday
patientsASA1and2 (G2)oralGpn300mg/daystarted Chronicpainoutcomes 10
scheduledforeitherpartialor thenightbeforesurgeryand T2(cid:1)6months
radicalmastectomy continuedfor10days postop
Meanage(SD):Ven(cid:1)45 (G3)placebo
years(6);Gpn(cid:1)43years
(5);C(cid:1)44years(8)
Broglyetal. Date:May–November2006 Perioperativeintervention Primaryoutcome:Postoprescue T1(cid:1)0–24hours
(2008)50 Design:RCT RCT:effectofGpnafterthyroid analgesicuseafter postop
N(cid:1)50(Gpn:n(cid:1)22;C: surgerywithSCPB thyroidectomywithSCPB T2(cid:1)6months
n(cid:1)21) F:(G1)oralGpn1200mggiven2 Secondaryoutcomes:Chronic postop
Samplecharacteristics:ASAI–III hoursbeforesurgery neuropathicpainoutcomes
patientsscheduledfortotal (G2)placebo
orpartialthyroidectomy AllpatientsreceivedaSCPB
withoutlymphnode
dissection
Meanage(range):Gpn(cid:1)
49(18–63)C(cid:1)49(25–72)
Burkeetal. Date:NR Perioperativeintervention Primaryoutcome:Changeinpain T1(cid:1)baseline
(2010)34 Design:RCT RCT:EffectofPregabonpainand intensityasmeasuredbya T2(cid:1)24hours
N(cid:1)40(Pregab:n(cid:1)20;C: functionaloutcomes3months visualanaloguescale((cid:5)VAS(cid:6), postop
n(cid:1)20) afterdiscectomy 0–100mm)fromthe T3(cid:1)3months
Samplecharacteristics:Low- F:(G1)oralPregab300mggiven preoperativeassessmenttothe postop
risk(ASA1and2)patients 90minutesbeforesurgery 3-monthfollow-up
withchroniclumbarsacral followedby150mgat12and Secondaryoutcomes:Preoperative
radiculopathyundergoing 24hourspostoperatively anxiolysis,disabilitymeasures,
electivelumbardiscectomy (G2)placebo health-relatedquality-of-life
Meanage:Pregab(cid:1)37 measures,quantitativesensory
years(7.8);C(cid:1)41 testingassessments(i.e.,pain
years(12.4) sensationthresholds),andDNA
analysisofCGH1andOPRM1
Buvanendran Date:August2006toAugust Perioperativeintervention Primaryoutcome:Areductionin T1(cid:1)perioperative
etal. 2007 RCT:EffectofPregabonpainafter theincidenceofneuropathic topostopday3
(2010)31 Design:RCT totalkneearthroplasty painat6monthsforthe T2(cid:1)1month
N(cid:1)240(Pregab:n(cid:1)120; F:(G1)oralPregab300mgbefore Pregab-treatedgroup postop
C:n(cid:1)120) surgeryandpregab50–150mg Secondaryoutcomes:Painscores T3(cid:1)3months
Samplecharacteristics:ASAI–III dailyandfor14daysaftertotal perioperatively.Opioid postop
patientsscheduledfortotal kneearthroplasty consumptionandadverse T4(cid:1)6months
kneearthroplasty (G2)placebo events postop
Meanage:Pregab(cid:1)64 Activekneeflexion3dayspostop,
years(8.3);C(cid:1)63.3 sleepdisturbance
years(8.9)
Clarkeetal. Date:May2006toApril2008 Perioperativeintervention Primaryoutcome:Opioid T1(cid:1)48hours
(2009)49 Design:3groupRCT RCT:Gpnaftertotalhip consumptionandpainscores postop
N(cid:1)126(PreopGpn:n(cid:1)38; arthroplasty atrestandwithmovementto T2(cid:1)6months
postopGpn:n(cid:1)38;C: F:(G1)preemptiveoralGpn600 48hours postop
n(cid:1)38) mggiven2hoursbeforesurgery Secondaryoutcomes:Incidenceand
Samplecharacteristics:ASAI–III (G2)oralGpn600mggivenin severityofchronicpain6months
patientsscheduledfortotal PACUimmediatelyaftersurgery postsurgery.Psychosocial
primaryhiparthroplasty (G3)placebo QuestionnaireHipArthroplasty
Meanage(SD):Preop Allpatientsreceivedarobust Painquestionnaire,Neuropathic
Gpn(cid:1)58.9years(9.4); perioperativemultimodalpain PainScale,TheHospitalAnxiety
postopGpn(cid:1)60.4 regimenthatconsistedof andDepressionScale
years(8.1);C(cid:1)61.3 acetaminophen,celecoxib,
years(10.7) dexamethasone,andspinal
anesthesia
(Continued)
August2012•Volume115•Number2 www.anesthesia-analgesia.org 431
GabapentinandPregabalinPreventChronicPostsurgicalPain
Table 2.(Continued)
Measurement
Study Designandsample Intervention Outcomemeasuresintravenous timepoints
Fassoulaki Date:NR Perioperativeintervention Primaryoutcomes:Supplemental T1(cid:1)periopto
etal. Design:3groupRCT RCT:Breastsurgery analgesicconsumptionuntil postopday10
(2002)51 N(cid:1)75(Mexil:n(cid:1)21;Gpn: F:(G1)oralMexil600mg/day postopday10.Painscoresat T2(cid:1)3months
n(cid:1)22;C:n(cid:1)24) startedthenightbeforesurgery restandwithmovementuntil postop
Samplecharacteristics:Low-risk andcontinuedfor10days postopday10
patientsASA1and2 (G2)oralGpn1200mg/daystarted Secondaryoutcomes:Incidence
scheduledforbreastcancer thenightbeforesurgeryand andseverityofchronicpain3
surgery continuedfor10days monthspostsurgery.Theuseof
Meanage(SD) (G3)placebo supplementalanalgesics3
Mexil(cid:1)46years(5);Gpn(cid:1)42 monthsaftersurgery
years(7);C(cid:1)45years(10)
Fassoulaki Date:March2001toJanuary Perioperativeintervention Primaryoutcomes:Supplemental T1(cid:1)periopto
etal. 2004 RCT:Effectofmultimodal analgesicconsumptionuntil postopday10
(2005)52 Design:RCT analgesiaandGpnonacute postopday8.Painscoresat T2(cid:1)3months
N(cid:1)50(Gpn:n(cid:1)25;C: andchronicpainafterbreast restandwithmovementuntil postop
n(cid:1)25) cancersurgery postopday8 T3(cid:1)6months
Samplecharacteristics:Low-risk F:(G1)Gpn400mgevery6 Secondaryoutcomes:Incidence postop
patientsASA1and2 hours,startingtheevening andseverityofchronicpain3
scheduledforbreastcancer beforesurgery(18:00)and and6monthspostsurgery.The
surgery continueduntiltheeighth useofsupplementalanalgesics
Meanage(SD):Gpn(cid:1)49 postopday.20gofEMLA 3and6monthsaftersurgery
years(8.4);C(cid:1)48 cream(2.5%oflidocaineand
years(8.1) 2.5%ofprilocaine)wasapplied
tothewoundareafromtheday
ofsurgeryuntilthethirdpostop
day.Intraoperatively,irrigation
ofthebrachialplexusandthe
third,fourth,andfifth
intercostalspaceswere
performedwith10mLof0.75%
ropivacaine(G2)placebo
Mooreetal. Date:November2007to Perioperativeintervention Primaryoutcomes:Postoppain T1(cid:1)24hours
(2011)45 November2008 RCT:EffectofGpnafterelective scoresatrestandwith postop
Design:RCT caesariandelivery movement24hoursafter T2(cid:1)3months
N(cid:1)46(Gpn:n(cid:1)23;C: F:(G1)oralGpn600mggiven2 surgery postop
n(cid:1)23) hoursbeforesurgery(G2) Secondaryoutcomes:
Samplecharacteristics:Low-risk placebo Supplementalanalgesicsand
patientsASA1and2 sideeffects24hoursafter
undergoingelectivecaesarian surgery.Incidenceandseverity
delivery ofchronicpain3months
Meanage(SD):Gpn(cid:1)35 postsurgery
years(5);C(cid:1)34years(6)
Pesonen Date:April2008toSeptember Perioperativeintervention Primaryoutcomes:Mean T1(cid:1)48hours
etal. 2009 RCT:effectofPregabonelderly parenteraloxycodone postop
(2011)53 Design:RCT patientsaftercardiacsurgery consumptionuntil48hours T2(cid:1)1month
N(cid:1)70(Pregab:n(cid:1)35;C: F:(G1)oralPregab150mgbefore aftersurgery postop
n(cid:1)35) surgeryandPregab75mgtwice Secondaryoutcomes:Painscores, T3(cid:1)3months
Samplecharacteristics:elderly dailyandfor5daysaftercardiac sedation,confusion,and postop
patients(cid:1)75yearsofage surgery nauseaandvomitingratesafter
scheduledtoundergoprimary (G2)placebo surgery.Incidenceandseverity
CABGwithCPBorsingle-valve ofchronicpain1and3months
repairorreplacementwith postsurgery
CPB
Meanage:Pregab(cid:1)79.5
years(75–89);C(cid:1)69.6
years(75–91)
(Continued)
432 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA
Table 2.(Continued)
Measurement
Study Designandsample Intervention Outcomemeasuresintravenous timepoints
Senetal. Date:NR Perioperativeintervention Primaryoutcome:Painscoresin T1(cid:1)24hours
(2009)48 Design:3groupRCT RCT:Acomparisonofintraoperative thesupineandsittingpositions postop
Design:3groupRCT ketamineinfusiontopreemptive until24hoursaftersurgery T2(cid:1)1month
N(cid:1)60(Ket:n(cid:1)20;Gpn: Gpnfortotalabdominal Secondaryoutcomes:Intravenous postop
n(cid:1)20;C:n(cid:1)20) hysterectomy patient-controlledanalgesia T3(cid:1)3months
Samplecharacteristics:Women F:(G1)Ket0.3mg/kgintravenous morphineconsumptionupto24 postop
undergoingtotalabdominal bolusbeforeincisionand0.05 hoursaftersurgery.Incidence T3(cid:1)3months
hysterectomy mg/kg/hinfusionuntiltheendof andseverityofincisionalpain postop
Meanage(SD):Ket(cid:1)46 surgery 1,3,and6monthspostsurgery T4(cid:1)6months
years(6);Gpn(cid:1)47 (G2)oralGpn1200mggiven1 postop
years(7);C(cid:1)46years(7) hourbeforesurgery
(G3)placebo
Senetal. Date:November2007to Perioperativeintervention Primaryoutcomes:Postoppain T1(cid:1)24hours
(2009)47 November2008 RCT:EffectofGpnafteringuinal scoresatrestandwith postop
Location:Istanbul,Turkey herniorrhaphy movement24hoursafter T2(cid:1)1month
Design:RCT F:(G1)oralGpn1200mggiven1 surgery postop
N(cid:1)59(Gpn:n(cid:1)30; hourbeforesurgery Secondaryoutcomes: T3(cid:1)3months
C:n(cid:1)29) (G2)placebo Supplementalanalgesicsand postop
Samplecharacteristics:Low-risk sideeffects24hoursafter T4(cid:1)6months
patientsASA1malepatients surgery.Incidenceandseverity postop
undergoinginguinalhernia ofchronicpain1,3,and6
repair monthspostsurgery
Meanage(SD):Gpn(cid:1)24
years(5.5);C(cid:1)24
years(5.3)
ASA(cid:1)AmericanSocietyofAnesthesiologists;CABG(cid:1)coronaryarterybypassgraft;C(cid:1)control;CPB(cid:1)cardiopulmonarybypass;EMLA(cid:1)eutecticmixtureof
localanesthetics;F(cid:1)frequencyoftreatment;G1(cid:1)group1;G2(cid:1)group2;G3(cid:1)group3;Gpn(cid:1)gabapentin;Ket(cid:1)ketamine;Mexil(cid:1)mexiletine;NR(cid:1)not
recorded;Postop(cid:1)postoperative;Pregab(cid:1)pregabalin;Preop(cid:1)preoperative;RCT(cid:1)randomizedcontrolledtrial;SCPB(cid:1)superficialcervicalplexusblock;
SD(cid:1)standarddeviation;T(cid:1)timepoint;Ven(cid:1)venlafaxine;VAS(cid:1)visualanaloguescale.
dosing administered. Two studies gave a 300-mg preopera- painscoreswasnotobservedduringthefirst24hoursafter
tivedoseandeithercontinuedthedrugfor2moredoses(150 surgery.50Usingtheneuropathicpaindiagnosticquestion-
mgat12hoursand24hoursaftersurgery)34orcontinueda naire(DN2)asadiagnostictool,Broglyetal.50foundthat
regimenof50to150mgofpregabalindailyfor2weeksafter 30% (7 of 24) of patients reported neuropathic pain in the
surgery.31 Thethirdpregabalintrialgaveasinglepreopera- placebo group in comparison with 4% (1 of 23) of
tive dose of 150 mg followed by 75 mg of pregabalin twice gabapentin-treatedpatientsat6monthsaftersurgery.
dailyfor5daysaftersurgery.53 Using a similar design (i.e., 1200 mg gabapentin (n (cid:1)
Eight of the included trials31,45,46,49–53 reported sufficient 30) 1 hour before inguinal herniorrhaphy with spinal
dataforinclusioninameta-analysis,theresultsofwhichare anesthesia), Sen et al.47 reported that patients who
presentedinFigure2.Therewasmoderateoverallstatistical received gabapentin had less intense pain at 1, 3, and 6
heterogeneity (I2 (cid:1) 36.6%), which was explained in part by
months after surgery. The gabapentin-treated patients
the specific drug administered. Specifically, heterogeneity
reported less interruption with their activities of daily
was lower within the subgroups of gabapentin (I2 (cid:1) 30.5%) living 1 month postsurgery.47
and pregabalin studies (I2 (cid:1) 0%). There was statistical evi- InanotherstudybySenetal.,4840womenwererandomly
dence (P (cid:1) 0.05) of different effects across the 2 subgroups assigned to receive placebo (n (cid:1) 20) versus intraoperative
(Fig.2).Notably,funnelplotsofthe8studiesincludedinthe ketamine until the end of surgery (n (cid:1) 20) versus 1200 mg
meta-analysissuggestapublicationbias(Fig.3);thisraisesthe
gabapentin1hourbeforetotalabdominalhysterectomy.Pa-
possibilitythatseveralnegativetrialsofgabapentinorprega-
tients who received gabapentin had lower pain scores and
balinhavenotbeenpublished.Thispossibilityofpublication
consumedfeweropioidsintheacutepostoperativeperiod(24
biaswassupportedbyformalstatisticaltestingthatbordered
onsignificance(P(cid:1)0.051). hours).Theincidenceofincisionalpainandpainintensityat
1,3,and6monthsaftersurgerywassignificantlylowerinthe
Preventive Effects of Gabapentin on CPSP gabapentingroupthanintheketamineandcontrolgroups.48
Of the 8 gabapentin trials, 447,48,50,52 reported that the Finally, Fassoulaki et al.52 found a reduction in pain and
perioperative use of gabapentin resulted in a lower inci- analgesic consumption using a multimodal analgesic regi-
dence of pain and/or lower analgesic requirements at men, which involved 50 women who underwent breast
long-term follow-up ((cid:1)2 months after surgery) (Table 3). cancersurgeryandwererandomlyassignedtoreceive1200
Broglyetal.50administered1200mgofgabapentin(n(cid:1)25) mggabapentin(for8postoperativedays)startingtheevening
or placebo (n (cid:1) 25) 2 hours before total thyroidectomy before surgery, a eutectic mixture of local anesthetic cream
surgery. Patients also received superficial cervical plexus (for3postoperativedays),andropivacaineinthewound(at
blocks; a significant difference in opioid consumption or wound closure) (n (cid:1) 25) and were compared with placebo
August2012•Volume115•Number2 www.anesthesia-analgesia.org 433
GabapentinandPregabalinPreventChronicPostsurgicalPain
Figure2.Effectsofgabapentinorpregabalinonthedevelopmentofchronicpainat3to6monthsaftersurgery,stratifiedbythespecificdrug
administered.Thepooledeffectisexpressedasapooledoddsratio(OR)withassociated95%confidenceintervals(CI).Theshadedsquares
representpointestimatesinindividualrandomizedcontrolledtrials.Theareaofeachsquarecorrelateswithitscontributiontowardsthepooled
summaryestimates.Horizontallinesdenote95%CIs.Theopendiamondsrepresentthepooledestimatesforallstudies,aswellasthe2
subgroups. The statistical heterogeneity, as measured by the I2 statistic, was 36.6% for the overall analysis, 30.5% for the gabapentin
subgroup, and 0% for the pregabalin subgroup. There was borderline statistical evidence (P (cid:1) 0.05) of a difference between the pooled
estimatesinthegabapentinandpregabalinsubgroups.
(n(cid:1)25).52Thegroupthatreceivedthemultimodalanalgesic
regimen used significantly less paracetamol and adjunctive
painmedicationsthandidcontrols;theyalsoreportedlower
painscoresatrestandwithmovementonearlypostoperative
days.At3monthsaftersurgery,thepatientswhowereinthe
multimodal analgesia group reported a significantly lower
incidence of chronic pain (82% versus 45%) and used fewer
supplemental analgesics (23% versus 0%) than did patients
whoreceivedonlyplacebo.Sixmonthsaftersurgery,57%of
control patients complained of chronic pain in comparison
with 30% in the treatment group; however, this was not a
statisticallysignificantfinding.
The remaining 4 studies reported no effect of gabap-
entinonpainorsupplementalanalgesicusemorethan2
months after surgery45,46,49,51 (Table 3). A closer exami-
nation of 2 of the negative gabapentin studies46,51
showed that, although there was no difference in the
Figure3.Funnelplottoassessforpublicationbias.Funnelplot41of incidenceorseverityofCPSPafterbreastcancersurgery
theeffectsizefromeachstudy(expressedasthenaturallogarithm at the 3-month and 6-month follow-ups, both studies
oftheoddsratio)againstameasureofresultprecisionfromeach found that patients who received gabapentin reported
trial(expressedastheSEofthelogoddsratio).Theasymmetryof
lessburningpainatthesetimepoints.Table4showsthe
the plot was suggestive of publication bias, which was further
confirmedthroughformaltesting(P(cid:1)0.051)usingthemethodof odds ratios comparing placebo-treated patients with
Harbordetal.42 gabapentin-orpregabalin-treatedpatientswithrespecttothe
434 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA
Table 3.Postoperative Results for Specified Outcomes
Quality/
Delphi (cid:1)2(cid:2)agent/
Outcome Study score preventiveeffects Postoperativeoutcomeresults*(P<0.05)
Chronicpostsurgical Amretal.(2010)46 7 Gabapentin,no Venlafaxinedemonstratedagreaterpreventiveeffect
pain withrespecttodecreasingchronicpainversus
placebo-treatedpatients(i.e.,lessburningand
stabbing/prickingpain)at6months.Patientswho
receivedgabapentinreportedlessburningthan
controlpatients
Broglyetal.(2008)51 6 Gabapentin,yes Significantlymorepatientsintheplacebogroup(7
outof24,30%)fittheDN2criterionforchronic
neuropathicpainthandidthepatientswho
receivedgabapentinafterthyroidsurgerywith
SCPB(1outof23,4.3%)6monthsaftersurgery
Burkeetal.(2010)34 8 Pregabalin,yes Resultsdemonstratedthatthe(mean(cid:7)SD)
decreaseintheVASpainscoreat3monthswas
greaterinpatientswhoreceived
pregabalin(37.6(cid:7)19.6mm)thanthosewho
receivedplacebo(25.3(cid:7)21.9mm)(P(cid:1)0.08)
Buvanendranetal.(2010)31 9 Pregabalin,yes Neuropathicpainwasabsentinthetreatment
group(0%)versusplacebo(8.7%)3monthsafter
totalkneearthroplastysurgeryandagain0%in
thetreatmentgroupversus5.2%intheplacebo
group6monthsaftersurgery
Clarkeetal.(2009)49 8 Gabapentin,no 6monthsaftertotalhipathroplastysurgery,the
incidenceandseverityofchronicpostsurgicalpain
wassimilarinallgroups
Fassoulakietal.(2002)51 7 Gabapentin,no 3monthsaftersurgery,theincidenceofchronic
pain,itsseverity,andtheneedforsupplemental
analgesicswerenotaffectedbyeither
intervention.Therewasareportofincreased
“burning”paininthecontrolgroupversusthe
other2groups
Fassoulakietal.(2005)52 7 Gabapentinandmultimodal 3and6monthsaftersurgery,18of22(82%)and
regimen,yes 12of21(57%)ofthecontrolsreportedchronic
painversus10of22(45%)and6of20(30%)in
thetreatmentgroup.Asignificantdifferencewas
evidentat3months,butnot6months
Mooreetal.(2011)45 8 Gabapentin,no 3monthsaftersurgery,theincidenceofchronic
pain,itsseverity,andtheneedforsupplemental
analgesicsweresimilarbetweengroups
Pesonenetal.(2011)53 8 Pregabalin,yes At3monthsaftersurgery,patientsintheplacebo
group(23%)experiencednon-zeropain
significantlymoreoftenthanpatientsinthe
pregabalingroup(4%)
Senetal.(2009)48 7 Gabapentin,yes Theseverityofincisionalpainwassignificantlyless
inthegabapentin-treatedgroupat1,3,and6
months
Senetal.(2009)47 8 Gabapentin,yes Theseverityofincisionalpainwassignificantlyless
inthegabapentin-treatedgroupat1,3,and6
months
Self-reportmeasures Amretal.(2010)46 7 GabapentinN/A Noself-reportmeasuresofdisabilityperformed
ofdisability/ Broglyetal.(2008)50 6 GabapentinN/A Noself-reportmeasuresofdisabilityperformed
physicalfunction Burkeetal.(2010)34 8 Pregabalin,yes TheRolandMorrisdisabilityscoreat3monthswas
significantlylowerinpatientswhoreceived
pregabalin(2.7(cid:7)2.4)thaninthosewhoreceived
placebo(5.6(cid:7)4.8)
Buvanendranetal.(2010)31 9 Pregabalin,yes TheKOOS–PSkneefunctionscore(0–100)was
improvedinpatientswhoreceivedperioperative
pregabalin(12.4(cid:7)5.5)versusplacebopatients
withchronicpain(49.0(cid:7)16.2)andanage-
matchednonchronicpainplacebo
cohort(25.7(cid:7)7.2)
(Continued)
August2012•Volume115•Number2 www.anesthesia-analgesia.org 435
GabapentinandPregabalinPreventChronicPostsurgicalPain
Table 3.(Continued)
Quality/
Delphi (cid:1)2(cid:2)agent/
Outcome Study score preventiveeffects Postoperativeoutcomeresults*(P<0.05)
Clarkeetal.(2009)49 8 Gabapentin,no Nodifferencebetweengroups:“Towhatextentdoes
yourhiparthroplastysitepaininterferewithyour
everydayactivities?”Painintensitywasalso
similarinbothgroupsat6monthswithbending
kneesto90degrees
Fassoulakietal.(2002)51 7 GabapentinN/A Noself-reportmeasuresofdisabilityperformed
Fassoulakietal.(2005)52 7 Gabapentinandmultimodal Noself-reportmeasuresofdisabilityperformed
regimenN/A
Mooreetal.(2011)45 8 Gabapentin,no Only1patientineachgroupreportedthatpain
limitedhisorherdailyfunction
Pesonenetal.(2011)53 8 Pregabalin,yes Noself-reportmeasuresofdisabilityperformed
Senetal.(2009)48 7 Gabapentin,yes Dailyactivitiesweresignificantlylessaffectedinthe
gabapentin-treatedpatientsat1and3months
aftersurgery,butnotat6months.Unfortunately,
datawerenotprovided,andthemagnitudeofthis
differencecannotbedetermined
Senetal.(2009)47 8 Gabapentin,no Asmallernumberofpatientsinthegabapentin-
treatedgroupreportedanimpairmentindaily
activities1monthaftersurgery.Nodifferencewas
seenat3and6monthsaftersurgery
Functionaloutcome Buvanendranetal.(2010)31 9 Pregabalin,yes Patientstreatedwithpregabalinhadgreateractive
measurement kneeflexion30daysaftersurgery
Significantside Buvanendranetal.(2010)31 9 Pregabalin,yes Patientswhoreceived300mgofpregabalin
effects preoperativelyfollowedby50–150mgof
pregabalinBIDexperiencedgreaterpostoperative
sedationandconfusion
Mooreetal.(2011)45 8 Gabapentin,no Patientsreceivinggabapentinweremorelikelyto
reporttheirsedationassevere(19%)than
patientsreceivingplacebo(0%)withinthefirst24
hourspostoperatively
Pesonenetal.(2011)53 8 Pregabalin,yes TheCAM–ICUconfusiontestscorewassignificantly
reducedintheplacebogrouponthefirstdayafter
extubation
BID (cid:1) twice a day; CAM–ICU (cid:1) the Confusion Assessment Method for Intensive Care Unit Patients; DN2 (cid:1) Neuropathic Pain Diagnostic Questionnaire;
KOOS–PS(cid:1)KneeOsteoarthritisOutcomeScore—PhysicalFunctionshortform;N/A(cid:1)notapplicable;SCPB(cid:1)superficialcervicalplexusblock;VAS(cid:1)visual
analoguescale.
outcomespresentedin6ofthe8gabapentintrials.Amongthe BurkeandShorten34randomlyassignedpatientstoreceive
6studiesthatcouldbeincludedinmeta-analysis,gabapentin either pregabalin (300 mg at 90 minutes preoperatively and
causedamoderate-to-largereductioninthedevelopmentof 150mgat12and24hourspostoperatively)(n(cid:1)20)orplacebo
CPSP(pooledOR0.52;95%CI,0.27to0.98;P(cid:1)0.04). (n (cid:1) 20) at corresponding times in a double-blind manner
while undergoing lumbar discectomy. The primary out-
Preventive Effects of Pregabalin on CPSP
come measure was a change in the intensity of pain as
Threestudiesexaminedthepreventiveeffectsofperiop-
measuredbyavisualanalogscalefromthepreoperative
erative pregabalin administration on the incidence and
assessment to 3-month follow-up. Visual analog scale
intensity of CPSP (Tables 2 and 3).31,34,53 All 3 studies pain scores were lower at 3 months (37.6 (cid:7) 19.6 mm) in
showed significant preventive analgesic effects in that
treated patients than in controls (25.3 (cid:7) 21.9 mm).34
there was a reduced incidence of pain and/or lower
analgesic requirements at long-term follow-up, (cid:1)2 Pesonenetal.randomlyassigned75elderlypatients(all
75 years or older) to receive either 150 mg of pregabalin
months after surgery. Buvanendran et al.31 randomized
before surgery and 75 mg of pregabalin BID for 5 postop-
patients to receive a 300-mg preoperative dose of prega-
erativedaysorplacebo.53Elderlypatientsinthisstudywho
balinfollowedbya14-daytwice-a-day(BID)regimenof
receivedpregabalinconsumedfewersupplementalanalge-
pregabalin (50 mg to 150 mg) or placebo after total knee
arthroplasty.31 The Leeds Assessment of Neuropathic sics in the acute hospital period and had lower confusion
Symptoms and Signs54 was used to diagnose the pres- assessmentscoresonpostoperativeday1.Theincidenceof
enceofchronicneuropathicpainat3and6monthsafter pain during movement was significantly lower in the
surgery. The results showed that 8.7% and 5.2% of
pregabalingroup3monthsaftersurgery.53Table4presents
placebo-treated patients experienced chronic neuro- the odds ratios for the outcomes reported in the 3 prega-
pathicpain3and6monthsaftersurgery,respectively.In balin trials. Within the 2 studies that could be included in
contrast, not a single patient in the pregabalin-treated themeta-analysis,pregabalincausedaverylargereduction
group was diagnosed with chronic neuropathic pain at inthedevelopmentofCPSP(pooledOR0.09;95%CI,0.02
either follow-up.31 to0.79;P(cid:1)0.007).
436 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA
Table 4.Odds Ratios for Reported Outcomes Comparing Placebo-Treated Patients with Gabapentin- or
Pregabalin-Treated Patients
Oddsratio
Study* Outcome (95%CI) Pvalue Interpretation
Amretal.46 IncidenceofCPSPat6months 0.48(0.16–1.43) 0.187 Gabapentin-treatedatnolowerriskthan
placebo-treated
Broglyetal.50 NumberofPatientswithDN2 0.11(0.01–0.99) 0.048 Gabapentin-treatedatlowerriskthan
score(cid:1)3at6months placebo-treated
Burkeetal.34 Numberofpatientsachievingagood 0.15(0.03–0.85) 0.031 Pregabalin-treatedatlowerriskofpoor
outcomeontheRMDQ functionaloutcomethanplacebo-treated
Buvanendranetal.31 CPSPat3months(S–LANS 0.04(0.003–0.76) 0.032 Pregabalin-treatedatlowerriskthanplacebo-
score(cid:8)12) treated
CPSPat6months(S–LANS 0.07(0.00–1.33) 0.077 Pregabalin-treatedatnolowerriskthan
score(cid:8)12) placebo-treated
Clarkeetal.49 CPSPat6months 1.15(0.44–2.95) 0.779 Gabapentin-treatedatnolowerriskthan
placebo-treated
Fassoulakietal.51 Incidenceofchronicpainat3months 0.78(0.25–2.47) 0.671 Gabapentin-treatedatnolowerriskthan
placebo-treated
Incidenceofburningpainat3months 0.11(0.01–1.03) 0.054 Gabapentin-treatedatnolowerriskthan
placebo-treated
Fassoulakietal.52 CPSPat3months 0.19(0.04–0.72) 0.015 Gabapentin-treatedatlowerriskthan
placebo-treated
CPSPat6months 0.19(0.05–0.73) 0.084 Gabapentin-treatedatlowerriskthan
placebo-treated
Mooreetal.45 CPSPat3months 0.57(0.09–3.61) 0.552 Gabapentin-treatedatnolowerriskthan
placebo-treated
Pesonenetal.53 CPSPat3months 0.11(0.01–0.91) 0.041 Pregabalin-treatedatlowerriskthanplacebo-
treated
CI(cid:1)confidenceinterval;CPSP(cid:1)chronicpostsurgicalpain;DN2(cid:1)NeuropathicPainDiagnosticQuestionnaire;RMDQ(cid:1)RolandMorrisDisabilityQuestionnaire;
S–LANS(cid:1)LeedsAssessmentofNeuropathicSymptomsandSignspainscale.
*DatafromSenetal.47,48notshowninpublishedarticlenorsupplieduponrequest.
Functional Outcomes and Disability Assessment DISCUSSION
Sixofthe11trialsincludedalong-termfunctionaloutcome We systematically reviewed the published literature on the
measureordisabilityassessment.31,34,45,47–49Thesestudies developmentofCPSP((cid:1)2monthsaftersurgery)afterperiop-
used self-report questionnaires to measure the impact of erative gabapentin or pregabalin administration. Our search
perioperativegabapentinandpregabalinondailyfunction yielded11trialspublishedbetween2002and2011.Ofthe11
in the long-term. The 4 gabapentin trials assessed this trials published, 8 were perioperative gabapentin trials, 4 of
outcome by asking the patients, “What impact does pain which (i.e., 50%) found that gabapentin decreased the inci-
currentlyhaveonyourdailyactivities?”45,47–49 denceofchronicpainthatpersistedformorethan2months
Fourofthe6trialsfoundthatperioperativegabapentin/ aftersurgery.Allpregabalintrials(3of3)demonstratedthat
pregabalin administration improved long-term functional pregabalin decreased the incidence of CPSP, and 2 of those
outcomes. Two gabapentin trials reported that a single trials also found an improvement in postsurgical patient
1200-mg dose of gabapentin was associated with improved function. These findings in individual trials were confirmed
dailyfunctioning1monthafteringuinalherniorrhaphy47and byourmeta-analysis,whichfoundthatgabapentinandprega-
1 and 3 months after total hysterectomy.48 Two pregabalin balincausedanoverallmoderate-to-largereductioninCPSP.
trials31,34usedvalidandreliabletoolstomeasurepostopera- The randomized controlled trials included in this sys-
tive functional disability. Three months after lumbar discec- tematicreviewareofmoderatetohighquality(meanDelphi
tomy the Roland Morris disability score was significantly score(cid:1)7.5/9).Fiftypercentofthegabapentintrialsand100%
lower in the patients who received perioperative pregabalin ofthepregabalintrialsdemonstratedapreventiveeffectwith
(2.7(cid:7)2.4)thaninthosewhoreceivedplacebo(5.6(cid:7)4.8).34 respecttotheincidence/intensityofchronicpostsurgicalpain.
UsingscoresfromtheKneeOsteoarthritisOutcomeScore— This is compelling, but early, evidence suggesting that the
PhysicalFunctionShort-form(KOOS–PS),55 Buvanendranet reductioninCPSPmaybelinkedtotheperioperativeadmin-
al.31reportedthatpatientswhowerediagnosedwithchronic istration of these medications. However, there are several
painat6months(allplacebotreated)hadsignificantlyworse shortcomingsintheliteraturereviewed.
KOOS–PSkneescores(49(cid:7)16.2)thandidpregabalin-treated All11trialshadsmallsamplesizesandappearedtobe
patients (12.4 (cid:7) 5.5). The KOOS–PS knee scores of the underpowered for the secondary outcomes related to the
pregabalin-treated patients were also significantly better incidence and severity of CPSP. The trial by Burke and
when compared with an age-matched nonchronic pain pla- Shorten34istheonlyonethatpoweredthestudy,apriori,
cebocohort(25.7(cid:7)7.2).31 todetectaneffectonchronicpostoperativepain3months
The remaining 2 gabapentin trials45,49 reported that a aftersurgery.34Importantly,andincontrasttotheother10
single600-mgdoseofgabapentindidnotaffectfunctional studies,BurkeandShorten34studiedthemagnitudeofthe
outcomesordisability3and6monthsaftersurgery. change from preoperative persistent lumbar back pain to
August2012•Volume115•Number2 www.anesthesia-analgesia.org 437
GabapentinandPregabalinPreventChronicPostsurgicalPain
CPSP as a function of the drug intervention. The other 10 pain.67 These recommendations include psychological, emo-
trialsusedpatientswithoutpreexistingpain,andreported tional, and physical variables in addition to those routinely
the effects of the intervention in relation to the incidence assessedinperioperativeanesthesiatrials(i.e.,painincidence
andseverityofCPSPwithoutanappropriatepowercalcu- and severity, and analgesic consumption). Assessment of
lationforthisendpoint. additionaldomainsofphysicalfunctionandtheexperienceof
Overall, the meta-analysis found very promising pain during those functional activities may help to identify
pooled effects of gabapentin and pregabalin; the magni- patient-related factors, which may impact the recovery pro-
tude of these effects, especially with respect to pregaba- cess after surgery; these factors may also be associated with
lingiventhelimitednumberofstudies(OR0.09),maybe thedevelopmentofCPSP.
clinically implausible. In addition, our analysis found Multimodalanalgesicregimensinvolvetheuseofdifferent
that publication bias might have exaggerated the re- classes of analgesic drugs to provide superior pain relief at
ported benefits of gabapentin and pregabalin. Conse- rest and with movement, reduce opioid consumption, and
quently,thismeta-analysis,whilepromising,shouldnot reduceanalgesic-relatedadverseeffects.68Usingmultimodal
be viewed as definitive. perioperative acute pain strategies (i.e., different classes of
Ofthe8gabapentintrialsincludedinthisreview,5ofthe medications that act on different nociceptive afferent and
studies used single-dose gabapentin 1 to 2 hours before efferentpathwaysintheperioperativesetting)hasbecomethe
surgery.45,47–50 The 3 trials that used 1200 mg gabapentin standard of care for many surgical populations.68 These
before surgery all reported that gabapentin reduced the strategies have demonstrated good acute pain reductions
incidenceandseverityofchronicpain.47,48,50The2trialsthat andopioidsparingintheshortterm.69,70Moredatathat
used a single 600-mg gabapentin administration 2 hours assess these regimens at preventive endpoints are
beforesurgeryfailedtoshowanyreductionintheincidence needed. One study in this review compared a compre-
orseverityofCPSPat3and6monthsaftersurgery.45,49This hensive multimodal perioperative regimen to placebo
islimitedevidencetosuggestthatusingahighpreoperative and found that patients treated with the multimodal
doseofgabapentin(i.e.,1200mg)ismoreeffectivethanusing regimenhadadecreasedincidenceandseverityofCPSP
low preoperative doses for the prevention of CPSP. Gabap- andusedlesssupplementalanalgesicsat3and6months.52The
entinathigherdosesinthepreoperativeperiodmayhavea obviouslimitationwiththisstudyandothersimilarstudiesis
greater effect on blunting the peripheral and central sensiti- the inability to determine to what extent each medication
zationprocessesthatoccurduringsurgery. affectedthetransitiontochronicpain.
Of the 3 remaining gabapentin studies (all the studies The field of human pain genetics is in its infancy. One
continued gabapentin into the postoperative time period), reviewsummarizedtherapidlyaccumulatingevidencefrom
only 152 demonstrated a significant pain reduction that per- animal models of CPSP and studies in human twins, which
sisted for 2 or more months after surgery. It has been well showed that chronic pain was a complex heritable trait.2
documented that the absorption profile of gabapentin in Severalstudieshaverecentlyreportedonpolymorphismsin
humans is inconsistent due to the active and saturable certain genes that predispose carriers to transition to pain
(cid:4)-aminoacidtransportsystem.56Thus,thebioavailabilityof chronicity.71–73 Burke and Shorten34 attempted to link their
any given dose varies from 35% to 90%.56 Without plasma findingstoknownhumangeneticpolymorphismsassociated
samples, one cannot confirm therapeutic drug concentra- with pain. They did not report significant associations with
tions of gabapentin; no trial identified in this systematic GCH1orOPRM1inthe38patientsfollowed.However,there
reviewtestedplasmalevelstoconfirmtherapeuticlevels. were several shortcomings to the genetic data presented,
The results from this systematic review suggest that includingtoofewpatients,theabsenceofadetaileddescrip-
pregabalinmayhaveamorepromisingandeffectiverole tion of the assays/methods used with respect to gene map-
in the prevention of CPSP syndromes, given its more ping, and appropriate input from genetic statisticians. This
reliable absorption profile ((cid:1)90% bioavailability of a information is essential for future researchers attempting to
single dose). Finally, although the results from this replicateandvalidatepositivegeneticfindings.
review suggest that higher doses of the (cid:4)-2-(cid:5) ligands
may produce greater antinociceptive efficacy, higher Novel Postulated Mechanisms of Action
dosesalsounreliablyincreasesomnolenceandconfusion of Gabapentinoids
in the clinical setting.57,58 It is not uncommon to have Theproposedmechanismofactionofgabapentinandprega-
patientswhohavebeengiven1200mgofgabapentin1to balinisbelievedtobetheselectiveinhibitorybindingtothe
2 hours before surgery present in the postoperative care (cid:4)2(cid:5)subunit of voltage-dependent calcium channels in acti-
unit completely awake, while others are almost com- vatedneurons.74Thebindingofgabapentintothe(cid:4)2(cid:5)subunit
pletely somnolent. reduces the expression of voltage-dependent calcium
ThefactorsinvolvedinthedevelopmentofCPSParenot channels.75 A point mutation in the (cid:4)2(cid:5)type 1 subunit
wellunderstood.Severalobservationalstudieshaveoutlined (R217A) prevents the binding of gabapentin to the cal-
highlyvariableratesofCPSPaftertotalkneearthroplasty,59 cium channel.76 The analgesic properties of both gabap-
total hip arthroplasty,59,60 cardiac surgery,61 mastectomy,62 entin and pregabalin are greatly reduced in mice ex-
inguinal hernia,63 cholecystectomy,64 and thoracotomy65,66 pressing this point mutation.77 The mutation also
populations. Future studies need to elaborate on the impact prevents the ability of gabapentin to reduce calcium
thatCPSPsyndromeshaveonpatientfunction.Tothatend, channel expression.75
recommendationshavebeenmadefortheassessmentofcore Severallinesofevidencesuggestthatthishigh-affinitysite
measures and domains in clinical trials focused on chronic contributes to, but may not fully account for, the analgesic
438 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA
propertiesofgabapentin.Theincreasedexpressionofthe(cid:4)2(cid:5) Toronto,Ontario,Canada;‡DepartmentofAnesthesia,Uni-
subunit that occurs in animal models of hyperalgesia is versity of Toronto, Toronto, Ontario, Canada; §Centre de
not a prerequisite for the short-term analgesic actions of Recherche Universite(cid:3) Laval Robert-Giffard, Universite(cid:3)
gabapentin.78 In addition, a comparison of the antinoci- Laval,Que(cid:3)bec,Canada;(cid:1)LibraryandInformationServices,
ceptivepropertiesofgabapentinandstereoisomericana- University Health Network, Toronto, Ontario, Canada; ¶Li
logues of gabapentin revealed a stereospecific analgesic Ka Shing Knowledge Institute of St. Michael’s Hospital,
effect of some but not all of the gabapentin analogues;79 Toronto, Ontario, Canada; #Institute of Health Policy Man-
agement and Evaluation, University of Toronto; **Depart-
butsurprisingly,someofthegabapentinanalogueswith
high affinity for the (cid:4)2(cid:5)subunit did not have antinoci- ment of Psychology and School of Kinesiology and Health
Science, York University, Toronto, Ontario, Canada.
ceptive properties.
Someevidencesuggeststhatthe(cid:4)2(cid:5)subunitalsoregu-
STUDYFUNDING
lates synaptogenesis through mechanisms that are inde-
HanceClarkeissupportedbyaCanadianInstitutesofHealth
pendent of Ca2(cid:2) channel function.80 Specifically, the (cid:4)2(cid:5)
ResearchPhDFellowshipAward.HanceClarkeandDuminda
subunitisareceptorforthrombospondins,proteinsthatare
Wijeysundera are supported by Merit Awards from the De-
secreted by astrocytes and promote synapse formation.81 partmentofAnesthesiaattheUniversityofToronto.Duminda
Gabapentindisruptstheinteractionbetweenthrombospon- WijeysunderaissupportedbyaClinicianScientistAwardfrom
dins and the (cid:4)2(cid:5)subunit, resulting in decreased synapse the Canadian Institutes of Health Research. Joel Katz is sup-
formation.80 The disruption of (cid:4)2(cid:5)subunit-mediated syn- ported by a Canada Research Chair in Health Psychology at
aptogenesis by gabapentin may also contribute to the YorkUniversity.
analgesiceffectsofgabapentinandpregabalin,particularly
forthetreatmentofchronicpain.
Gabapentinandpregabalinhavebeenproposedtoact
throughawidevarietyofmechanismsbeyondinhibiting APPENDIX 1.Search Terms
the actions of the (cid:4)2(cid:5) subunit protein. Gabapentin Pregabalinorgabapentin- Perioperative/preemptive/
inhibits glutamate release, increases the activity of relatedterms preventiveandrelatedterms
N-methyl-d-aspartate receptors, inhibits the activity of Pregabalin expperioperativecare/
lyrica intraoperativecare/
voltage-gated sodium channels, and enhances the activ-
Gabapentin postoperativecare/
ity of voltage-gated potassium channels.82 Additionally,
60142-96-3.rn.(registry preoperativecare/
prolonged exposure to gabapentin can increase the am- number)
plitude of a tonic inhibitory GABAergic conductance83 neurontin expAnesthesiaRecoveryPeriod/
that may regulate pain processes.84 However, it remains ((alphaadj2delta)or perioperat*
(alpha2delta.mp)AND
to be determined whether these mechanisms contribute
expCalciumchannel
to the analgesic effects of gabapentin and pregabalin.
blockers/
peri-operat*
CONCLUSIONS peroperat*
postop*
Oursystematicreviewfoundpromisingresultsforgabapen-
Chronicpain-relatedterms post-op*
tin with respect to the reduction of CPSP. Commonalities expchronicdiseases/AND preoperat*
among the 4 positive studies should be explored in future exppain/
trials given that there appears to be emerging basic science (chronic*adj4pain*) pre-operat*
intraoperat*
datatosupportitsplausibilitywithrespecttotheprevention
intra-operat*
of CPSP. The 3 pregabalin trials included in this systematic
(beforeadj2surgery)
review reported even greater promise in preventing the (beforeadj2operat*4)
conversion from acute pain to CPSP. The improved absorp- (prioradj2surgery)
tion profile of pregabalin may be a primary reason for its (prioradj2operat*4)
operation?
improvedefficacy.Thestudyoftheantecedentpatient-related
operative*
factors that may also predict the development of CPSP is (surgeryorsurgeriesorsurgeon?or
important,andfuturestudiesshouldexpandcurrentoutcome surgical*)
domains.Appropriatemeasuresofpsychologicalandphysi- su.fs.(surgeryfloatingsubheading)
cal functioning should be included, along with measures of expsurgicalprocedures,operative/
expAnesthesiology/
chronic pain incidence and severity. Given the limited
anesthes*
number of studies identified in our review, the clinical anaesthes*
heterogeneity of the trials identified, and the suggestion expAnesthesia/
that a publication bias may be present, future well- anesthe*.jn,in.(journalorinstitution)
anaesthe*.jn,in.(journalor
designed, appropriately powered studies are needed to
institution)
clarify whether gabapentin and pregabalin have a peri-
preincision?
operative role in the prevention of CPSP. pre-incision?
postincision?
AUTHORAFFILITATIONS post-incision?
preemptive*
From the *Department of Anesthesia and Pain Management,
pre-emptive*
TorontoGeneralHospital,Toronto,Ontario,Canada;†Depart-
preventive*
ment of Anesthesia, Sunnybrook Health Sciences Centre,
August2012•Volume115•Number2 www.anesthesia-analgesia.org 439
GabapentinandPregabalinPreventChronicPostsurgicalPain
DISCLOSURES 10. Mathiesen O, Jacobsen LS, Holm HE, Randall S, Adamiec-
Name:HanceClarke,MSc,MD,FRCPC. MalmstroemL,GraungaardBK,HolstPE,HilstedKL,DahlJB.
Pregabalinanddexamethasoneforpostoperativepaincontrol:
Contribution: This author designed and conducted the re-
a randomized controlled study in hip arthroplasty. Br J An-
searchstudyandwrotethemanuscript.
aesth2008;101:535–41
Attestation:HanceClarkehasseentheoriginalstudydata,reviewed
11. Pandey CK, Priye S, Singh S, Singh U, Singh RB, Singh PK.
theanalysisofthedata,andapprovedthefinalmanuscript. Preemptiveuseofgabapentinsignificantlydecreasespostop-
Name:RobertP.Bonin,PhD. erativepainandrescueanalgesicrequirementsinlaparoscopic
Contribution:Thisauthorhelpedtowritethemanuscript. cholecystectomy.CanJAnaesth2004;51:358–63
Attestation: Robert P. Bonin has approved the final 12. McCartney CJ, Sinha A, Katz J. A qualitative systematic
reviewoftheroleofN-methyl-D-aspartatereceptorantago-
manuscript.
nists in preventive analgesia. Anesth Analg 2004;98:
Name:BeverleyA.Orser,MD,PhD,FRCPC.
1385–400
Contribution: This author designed and conducted the re- 13. Clarke H, Woodhouse L, Kennedy D, Stratford P, Katz J.
searchstudyandwrotethemanuscript. Strategies aimed at preventing chronic post-surgical pain:
Attestation: Beverley Orser has seen the original study data, re- comprehensive peri-operative pain management after total
viewedtheanalysisofthedata,andapprovedthefinalmanuscript. jointreplacementsurgery.PhysiotherCan2011;63:289–304
14. KatzJ,ClarkeH,SeltzerZ.Preventiveanalgesia:quovadimus?
Name:MarinaEnglesakis,BA,MLIS.
AnesthAnalg2011;113:1242–53
Contribution: This author designed and conducted the re-
15. LoeserJD,TreedeRD.TheKyotoprotocolofIASPbasicpain
searchstudyandwrotethemanuscript. terminology.Pain2008;137:473–7
Attestation: Marina Englesakis has seen the original study 16. CostiganM,ScholzJ,WoolfCJ.Neuropathicpain:amaladap-
data,reviewedtheanalysisofthedata,andapprovedthefinal tive response of the nervous system to damage. Ann Rev
manuscript. Neurosci2009;32:1–32
17. Ifuku M, Iseki M, Hidaka I, Morita Y, Komatus S, Inada E.
Name:DumindaN.Wijeysundera,MD,PhD,FRCPC.
Replacement of gabapentin with pregabalin in postherpetic
Contribution: This author designed and conducted the re-
neuralgiatherapy.PainMed2011;12:1112–6
searchstudyandwrotethemanuscript. 18. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden
Attestation: Duminda N. Wijeysundera has seen the original RL. Nortriptyline and gabapentin, alone and in combination
study data, reviewed the analysis of the data, and approved for neuropathic pain: a double-blind, randomised controlled
thefinalmanuscript. crossovertrial.Lancet2009;374:1252–61
19. Katz J. Pre-emptive analgesia: evidence, current status and
Name:JoelKatz,PhD.
futuredirections.EurJAnaesthesiolSuppl1995;10:8–13
Contribution: This author designed and conducted the re-
20. Kissin I. Preemptive analgesia: terminology and clinical rel-
searchstudyandwrotethemanuscript.
evance.AnesthAnalg1994;79:809–10
Attestation: Joel Katz has seen the original study data, re- 21. Wall PD. The prevention of postoperative pain. Pain
viewed the analysis of the data, and approved the final 1988;33:289–90
manuscript. 22. Katz J, Clarke H. Preventive analgesia and beyond: current
Thismanuscriptwashandledby:SpencerS.Liu,MD. status, evidence, and future directions. In: Macintyre PE,
Rowbotham DJ, Howard R, eds. Clinical Pain Management:
AcutePain.2nded.London:HodderArnoldLtd.,2008:154–98
REFERENCES 23. GuayDR.Updateongabapentintherapyofneuropathicpain.
1. MacraeW,DaviesH.Chronicpostsurgicalpain.In:Crom- ConsultPharm2003;18:158–70,173–8
bie IK, Linton S, Croft P, Von Knorff M, LeResche L, eds. 24. Laird MA, Gidal BE. Use of gabapentin in the treatment of
Epidemiology of Pain. Washington, DC: IASP Press, neuropathicpain.AnnPharmacother2000;34:802–7
1999:125–42 25. MoulinDE,ClarkAJ,GilronI,WareMA,WatsonCP,SessleBJ,
2. KatzJ,SeltzerZ.Transitionfromacutetochronicpostsurgical CoderreT,Morley-ForsterPK,StinsonJ,BoulangerA,PengP,
pain:riskfactorsandprotectivefactors.ExpertRevNeurother FinleyGA,TaenzerP,SquireP,DionD,CholkanA,GilaniA,
2009;9:723–44 GordonA,HenryJ,JoveyR,LynchM,Mailis-GagnonA,Panju
3. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: A, Rollman GB, Velly A. Pharmacological management of
riskfactorsandprevention.Lancet2006;367:1618–25 chronic neuropathic pain—consensus statement and guide-
4. KatzJ.Painbegetspain—predictorsoflong-termphantomlimb lines from the Canadian Pain Society. Pain Res Manag
painandpost-thoracotomypain.PainForum1997;6:140–4 2007;12:13–21
5. Perkins FM, Kehlet H. Chronic pain as an outcome of 26. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative
surgery. A review of predictive factors. Anesthesiology pain—a systematic review of randomized controlled trials.
2000;93:1123–33 Pain2006;126:91–101
6. ApfelbaumJL,ChenC,MehtaSS,GanTJ.Postoperativepain 27. Peng PW, Wijeysundera DN, Li CC. Use of gabapentin for
experience:resultsfromanationalsurveysuggestpostopera- perioperativepaincontrol—ameta-analysis.PainResManag
tive pain continues to be undermanaged. Anesth Analg 2007;12:85–92
2003;97:534–40 28. Seib RK, Paul JE. Preoperative gabapentin for postoperative
7. Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in analgesia:ameta-analysis.CanJAnaesth2006;53:461–9
postoperativepainmanagement:currentevidenceandfuture 29. Gajraj NM. Pregabalin: its pharmacology and use in pain
directions.Anesthesiology2003;99:1198–208 management.AnesthAnalg2007;105:1805–15
8. Adam F, Chauvin M, Du Manoir B, Langlois M, Sessler DI, 30. FieldMJ,OlesRJ,LewisAS,McClearyS,HughesJ,SinghL.
FletcherD.Small-doseketamineinfusionimprovespostopera- Gabapentin (neurontin) and S-((cid:2))-3-isobutylgaba represent a
tiveanalgesiaandrehabilitationaftertotalkneearthroplasty. novelclassofselectiveantihyperalgesicagents.BrJPharmacol
AnesthAnalg2005;100:475–80 1997;121:1513–22
9. Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. 31. Buvanendran A, Kroin JS, Della Valle CJ, Kari M, Moric M,
Preoperativegabapentindecreasesanxietyandimprovesearly TumanKJ.Perioperativeoralpregabalinreduceschronicpain
functional recovery from knee surgery. Anesth Analg aftertotalkneearthroplasty:aprospective,randomized,con-
2005;100:1394–9 trolledtrial.AnesthAnalg2010;110:199–207
440 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA
32. MathiesenO,RasmussenML,DierkingG,LechK,HilstedKL, 52. Fassoulaki A, Triga A, Melemeni A, Sarantopoulos C. Multi-
FomsgaardJS,LoseG,DahlJB.Pregabalinanddexamethasone modal analgesia with gabapentin and local anesthetics pre-
incombinationwithparacetamolforpostoperativepaincon- vents acute and chronic pain after breast surgery for cancer.
trolafterabdominalhysterectomy.Arandomizedclinicaltrial. AnesthAnalg2005;101:1427–32
ActaAnaesthesiolScand2009;53:227–35 53. PesonenA,Suojaranta-YlinenR,HammarenE,KontinenVK,
33. IttichaikultholW,VirankabutraT,KunopartM,KhamhomW, RaivioP,TarkkilaP,RosenbergPH.Pregabalinhasanopioid-
PutarawuthichaiP,RungphetS.Effectsofpregabalinonpost sparing effect in elderly patients after cardiac surgery: a
operative morphine consumption and pain after abdominal randomized placebo-controlled trial. Br J Anaesth
hysterectomy with/without salphingo-oophorectomy: a ran- 2011;106:873–81
domized,double-blindtrial.JMedAssocThai2009;92:1318–23 54. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS
34. Burke SM, Shorten GD. Perioperative pregabalin improves scoreforidentifyingpainofpredominantlyneuropathicorigin:
pain and functional outcomes 3 months after lumbar discec- validation for use in clinical and postal research. J Pain
tomy.AnesthAnalg2010;110:1180–5 2005;6:149–58
35. FreedmanBM,O’HaraE.Pregabalinhasopioid-sparingeffects 55. PerruccioAV,StefanLohmanderL,CanizaresM,TennantA,
following augmentation mammaplasty. Aesthet Surg J HawkerGA,ConaghanPG,RoosEM,JordanJM,MaillefertJF,
2008;28:421–4 DougadosM,DavisAM.Thedevelopmentofashortmeasure
36. Cabrera Schulmeyer MC, de la Maza J, Ovalle C, Farias C, of physical function for knee OA KOOS—Physical Function
Vives I. Analgesic effects of a single preoperative dose of Shortform (KOOS-PS)—an OARSI/OMERACT initiative. Os-
pregabalin after laparoscopic sleeve gastrectomy. Obes Surg teoarthritisCartilage2008;16:542–50
2010;20:1678–81 56. ChengJK,ChiouLC.Mechanismsoftheantinociceptiveaction
37. Deletedinproof. ofgabapentin.JPharmacolSci2006;100:471–86
38. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, 57. PandeyCK,NavkarDV,GiriPJ,RazaM,BehariS,SinghRB,
Bouter LM, Knipschild PG. The Delphi list: a criteria list for SinghU,SinghPK.Evaluationoftheoptimalpreemptivedose
qualityassessmentofrandomizedclinicaltrialsforconducting ofgabapentinforpostoperativepainreliefafterlumbardiske-
systematic reviews developed by Delphi consensus. J Clin ctomy:arandomized,double-blind,placebo-controlledstudy.
Epidemiol1998;51:1235–41 JNeurosurgAnesthesiol2005;17:65–8
39. Higgins JP, Thompson SG. Quantifying heterogeneity in a 58. White PF, Tufanogullari B, Taylor J, Klein K. The effect of
meta-analysis.StatMed2002;21:1539–58 pregabalin on preoperative anxiety and sedation levels: a
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring dose-rangingstudy.AnesthAnalg2009;108:1140–5
inconsistencyinmeta-analyses.BMJ2003;327:557–60 59. WyldeV,HewlettS,LearmonthID,DieppeP.Persistentpain
41. Egger M, Davey Smith G, Schneider M, Minder C. Bias in after joint replacement: prevalence, sensory qualities, and
meta-analysis detected by a simple, graphical test. BMJ postoperativedeterminants.Pain2011;152:566–72
1997;315:629–34 60. Nikolajsen L, Brandsborg B, Lucht U, Jensen TS, Kehlet H.
42. HarbordRM,EggerM,SterneJA.Amodifiedtestforsmall- Chronic pain following total hip arthroplasty: a nationwide
studyeffectsinmeta-analysesofcontrolledtrialswithbinary questionnairestudy.ActaAnaesthesiolScand2006;50:495–500
endpoints.StatMed2006;25:3443–57 61. BruceJ,DruryN,PoobalanAS,JeffreyRR,SmithWC,Cham-
43. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, bers WA. The prevalence of chronic chest and leg pain
IoannidisJP,ClarkeM,DevereauxPJ,KleijnenJ,MoherD.The following cardiac surgery: a historical cohort study. Pain
PRISMAstatementforreportingsystematicreviewsandmeta- 2003;104:265–73
analyses of studies that evaluate healthcare interventions: 62. BruceJ,PoobalanAS,SmithWC,ChambersWA.Quantitative
explanationandelaboration.BMJ2009;339:b2700 assessmentofchronicpostsurgicalpainusingtheMcGillPain
44. MoherD,LiberatiA,TetzlaffJ,AltmanDG.Preferredreport- Questionnaire.ClinJPain2004;20:70–5
ing items for systematic reviews and meta-analyses: the 63. Aasvang E, Kehlet H. Surgical management of chronic pain
PRISMAstatement.BMJ2009;339:b2535 afteringuinalherniarepair.BrJSurg2005;92:795–801
45. MooreA,CostelloJ,WieczorekP,ShahV,TaddioA,Carvalho 64. BisgaardT,RosenbergJ,KehletH.Fromacutetochronicpain
JC.Gabapentinimprovespostcesareandeliverypainmanage- after laparoscopic cholecystectomy: a prospective follow-up
ment: a randomized, placebo-controlled trial. Anesth Analg analysis.ScandJGastroenterol2005;40:1358–64
2011;112:167–73 65. Wildgaard K, Ravn J, Nikolajsen L, Jakobsen E, Jensen TS,
46. Amr YM, Yousef AAA-M. Evaluation of efficacy of the peri- Kehlet H. Consequences of persistent pain after lung cancer
operative administration of Venlafaxine or gabapentin on surgery:anationwidequestionnairestudy.ActaAnaesthesiol
acute and chronic postmastectomy pain. Clin J Pain Scand2011;55:60–8
2010;26:381–5 66. GuastellaV,MickG,SorianoC,ValletL,EscandeG,DubrayC,
47. SenH,SizlanA,YanaratesO,SenolMG,InangilG,SuculluI, EschalierA.Aprospectivestudyofneuropathicpaininduced
Ozkan S, Dagli G. The effects of gabapentin on acute and bythoracotomy:incidence,clinicaldescription,anddiagnosis.
chronicpainafteringuinalherniorrhaphy.EurJAnaesthesiol Pain2011;152:74–81
2009;26:772–6 67. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen
48. SenH,SizlanA,YanaratesO,EmirkadiH,OzkanS,DagliG, MP,KatzNP,KernsRD,StuckiG,AllenRR,BellamyN,CarrDB,
TuranA.Acomparisonofgabapentinandketamineinacute Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR,
and chronic pain after hysterectomy. Anesth Analg KramerLD,ManningDC,MartinS,McCormickCG,McDermott
2009;109:1645–50 MP,McGrathP,QuessyS,RappaportBA,RobbinsW,Robinson
49. Clarke H, Pereira S, Kennedy D, Andrion J, Mitsakakis N, JP,RothmanM,RoyalMA,SimonL,StaufferJW,SteinW,Tollett
Gollish J, Katz J, Kay J. Adding gabapentin to a multimodal J,WernickeJ,WitterJ.Coreoutcomemeasuresforchronicpain
regimen does not reduce acute pain, opioid consumption or clinicaltrials:IMMPACTrecommendations.Pain2005;113:9–19
chronic pain after total hip arthroplasty. Acta Anaesthesiol 68. JoshiGP.Multimodalanalgesiatechniquesandpostoperative
Scand2009;53:1073–83 rehabilitation.AnesthesiolClinNorthAm2005;23:185–202
50. BroglyN,WattierJM,AndrieuG,PeresD,RobinE,KipnisE, 69. ClarkeH,PereiraS,KennedyD,GilronI,KatzJ,GollishJ,Kay
Arnalsteen L, Thielemans B, Carnaille B, Pattou F, Vallet B, J.Gabapentindecreasesmorphineconsumptionandimproves
LebuffeG.Gabapentinattenuateslatebutnotearlypostopera- functionalrecoveryfollowingtotalkneearthroplasty.PainRes
tivepainafterthyroidectomywithsuperficialcervicalplexus Manag2009;14:217–22
block.AnesthAnalg2008;107:1720–5 70. HorlockerTT,KoppSL,PagnanoMW,HeblJR.Analgesiafor
51. FassoulakiA,PatrisK,SarantopoulosC,HoganQ.Theanal- totalhipandkneearthroplasty:amultimodalpathwayfeatur-
gesiceffectofgabapentinandmexiletineafterbreastsurgery ing peripheral nerve block. J Am Acad Orthop Surg
forcancer.AnesthAnalg2002;95:985–91 2006;14:126–35
August2012•Volume115•Number2 www.anesthesia-analgesia.org 441
GabapentinandPregabalinPreventChronicPostsurgicalPain
71. CostiganM,BelferI,GriffinRS,DaiF,BarrettLB,CoppolaG, 78. LuoZD,ChaplanSR,HigueraES,SorkinLS,StaudermanKA,
WuT,KiselycznykC,PoddarM,LuY,DiatchenkoL,SmithS, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion
Cobos EJ, Zaykin D, Allchorne A, Shen PH, Nikolajsen L, (alpha)2(delta)calciumchannelsubunitanditscorrelationwith
KarppinenJ,MannikkoM,KelempisiotiA,GoldmanD,Maix- allodyniainspinalnerve-injuredrats.JNeurosci2001;21:1868–75
nerW,GeschwindDH,MaxMB,SeltzerZ,WoolfCJ.Multiple 79. UrbanMO,RenK,ParkKT,CampbellB,AnkerN,StearnsB,
chronic pain states are associated with a common amino Aiyar J, Belley M, Cohen C, Bristow L. Comparison of the
acid-changingalleleinKCNS1.Brain2010;133:2519–27 antinociceptiveprofilesofgabapentinand3-methylgabapentin
72. TegederI,CostiganM,GriffinRS,AbeleA,BelferI,SchmidtH, in rat models of acute and persistent pain: implications for
Ehnert C, Nejim J, Marian C, Scholz J, Wu T, Allchorne A, mechanismofaction.JPharmacolExpTher2005;313:1209–16
Diatchenko L, Binshtok AM, Goldman D, Adolph J, Sama S, 80. Eroglu C, Allen NJ, Susman MW, O’Rourke NA, Park CY,
Atlas SJ, Carlezon WA, Parsegian A, Lotsch J, Fillingim RB, OzkanE,ChakrabortyC,MulinyaweSB,AnnisDS,Huberman
MaixnerW,GeisslingerG,MaxMB,WoolfCJ.GTPcyclohy- AD, Green EM, Lawler J, Dolmetsch R, Garcia KC, Smith SJ,
drolaseandtetrahydrobiopterinregulatepainsensitivityand Luo ZD, Rosenthal A, Mosher DF, Barres BA. Gabapentin
persistence.NatMed2006;12:1269–77 receptoralpha2delta-1isaneuronalthrombospondinreceptor
73. NissenbaumJ,DevorM,SeltzerZ,GebauerM,MichaelisM, responsibleforexcitatoryCNSsynaptogenesis.Cell2009;139:
Tal M, Dorfman R, Abitbul-Yarkoni M, Lu Y, Elahipanah T, 380–92
delCanhoS,MinertA,FriedK,PerssonAK,ShpiglerH,Shabo 81. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE,
E,YakirB,PisanteA,DarvasiA.Susceptibilitytochronicpain HellJW,AgahA,LawlerJ,MosherDF,BornsteinP,BarresBA.
following nerve injury is genetically affected by CACNG2. Thrombospondins are astrocyte-secreted proteins that pro-
GenomeRes2010;20:1180–90 moteCNSsynaptogenesis.Cell2005;120:421–33
74. Taylor CP. Mechanisms of analgesia by gabapentin and 82. Sills GJ. The mechanisms of action of gabapentin and prega-
pregabalin—calcium channel alpha2-delta [Cavalpha2-delta] balin.CurrOpinPharmacol2006;6:108–13
ligands.Pain2009;142:13–6 83. Cheng VY, Bonin RP, Chiu MW, Newell JG, MacDonald JF,
75. MichPM,HorneWA.AlternativesplicingoftheCa2(cid:2)channel OrserBA.Gabapentinincreasesatonicinhibitoryconductance
beta4 subunit confers specificity for gabapentin inhibition of inhippocampalpyramidalneurons.Anesthesiology2006;105:
Cav2.1trafficking.MolPharmacol2008;74:904–12 325–33
76. WangM,OffordJ,OxenderDL,SuTZ.Structuralrequirement 84. Bonin RP, Labrakakis C, Eng DG, Whissell PD, Koninck YD,
of the calcium-channel subunit alpha2delta for gabapentin Orser BA. Pharmacological enhancement of delta-subunit-
binding.BiochemJ1999;342:313–20 containingGABA(A)receptorsthatgenerateatonicinhibitory
77. FieldMJ,CoxPJ,StottE,MelroseH,OffordJ,SuTZ,Bramwell conductanceinspinalneuronsattenuatesacutenociceptionin
S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, mice.Pain2011;152:1317–26
DolphinAC,WebbT,WilliamsD.Identificationofthealpha2-
delta-1 subunit of voltage-dependent calcium channels as a
molecular target for pain mediating the analgesic actions of
pregabalin.ProcNatlAcadSciUSA2006;103:17537–42
442 www.anesthesia-analgesia.org ANESTHESIA&ANALGESIA